Main takeaway: The company does not want to follow in the shoes of others by raising capital to fully purchase new assets. It is confident in its growth pipeline of diverse products.
AFT Pharmaceuticals is satisfied with its approach to innovation and product development and wouldn’t consider capital raising to outright purchase new intellectual property.
During AFT’s interim investor call, co-founder and chief executive Hartley Atkinson made reference to a Singaporean
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Main takeaway: The company does not want to follow in the shoes of others by raising capital to fully purchase new assets. It is confident in its growth pipeline of diverse products.
